Class Action

Aspercreme Pain Relief Patch

Class Action

Aspercreme Pain Relief Patch

Case Name
(Date)
Cruz et al v. Sanofi US Corp.
21-cv-5536, N.D. Cal.
(May 2021)
Product/Service Aspercreme Pain Relief Patch
Allegations Making misleading pain relief claims

Misleadingly marketing the product as “Max Strength” when other products deliver more lidocaine and are more effective

Misleadingly marketing the patch as “fast acting” when it does not provide immediate pain relief

Falsely claim that the product provides 12 hours of relief when the patch does not stay on for even six hours

Falsely marketing the product as compliant with FDA regulations when it is not

Status Pending

The Latest

Filters

Aspercreme

Ad Alert

Aspercreme

TINA.org investigates after doctor challenges pain reliever’s “clinically proven” labeling claim on Twitter.